MET genetic lesions in non-small-cell lung cancer: pharmacological and clinical implications.

about

A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy

P2860

Q37352435-11BB353B-A2B3-4B43-A1A3-CA5FE395FD92

P2860

MET genetic lesions in non-small-cell lung cancer: pharmacological and clinical implications.

Item

http://www.wikidata.org/entity/Q38389999

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

MET genetic lesions in non-sma ...... cal and clinical implications.

@en

type

Item

label

MET genetic lesions in non-sma ...... cal and clinical implications.

@en

prefLabel

MET genetic lesions in non-sma ...... cal and clinical implications.

@en

P1476

MET genetic lesions in non-sma ...... cal and clinical implications.

@en

P2093

Giulia M Stella

http://www.w3.org/2001/XMLSchema#string

Laura Saracino

http://www.w3.org/2001/XMLSchema#string

Simona Ferrari

http://www.w3.org/2001/XMLSchema#string

P2860

The Hallmarks of Cancer

The zinc-finger protein slug causes desmosome dissociation, an initial and necessary step for growth factor-induced epithelial-mesenchymal transition

Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

Epithelial-mesenchymal transitions in tumour progression

P304

194-207

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3978/J.ISSN.2218-6751.2012.09.03

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Michele Zorzetto

Simona Inghilleri

P577

2012-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25806181

http://www.w3.org/2001/XMLSchema#string

P932

4367558

http://www.w3.org/2001/XMLSchema#string

MET genetic lesions in non-small-cell lung cancer: pharmacological and clinical implications.

about

P2860

P2860

MET genetic lesions in non-small-cell lung cancer: pharmacological and clinical implications.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932